Retinal Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Retinal Biologics market is segmented by Drug Class (VEGF-A Antagonist, TNF-a Inhibitor), Disease Indication (Macular Degeneration, Diabetic Retinopathy, Uveitis, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments.

Retinal Biologics Market Size

Retinal Biologics Market Summary
Study Period: 2018 - 2028
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.8 %

Major Players

Retinal Biologics Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and it's growth?

Retinal Biologics Market Analysis

The retinal biologics market studied is anticipated to record a CAGR of nearly 6.8% during the forecast period 2022-2027.

The emergence of the COVID-19 pandemic had an adverse effect on the world economy and the healthcare system. The global lockdown has affected the supply chain of pharmaceuticals, medical devices, and biotechnological products. On the other hand, research and development have come into focus. All government agencies and healthcare players have come forward to support the development of diagnostics and treatment methods for COVID-19. As per the study "Retinal findings in patients with COVID-19: Results from the SERPICO-19 study," published in September 2020, COVID-19 could affect the retina. Retinal veins diameter seems directly correlated with the disease severity. Thus, during COVID-19, retinal diseases increased, impacting the demand for retinal biologics, thereby driving the market.

Certain factors driving the market growth include the rising burden of retinal diseases, the increasing diabetic patient population, increasing R&D activities, and the growing number of FDA approvals.

There has been a tremendous increase in the diabetic population, across the globe, over the past decade. Several reports and surveys documented a drastic increase in the diabetic population based on the changing lifestyle and habits. For instance, according to the Asian Diabetics Prevention Initiatives, in 2020, 60% of the diabetic population globally lived in Asia. The higher contribution of diabetes burden are China and India, which is 113.9 million and 65.1 million adults with diabetes in China and India, respectively, and by 2030, both China and India combined may have almost half a billion diabetic patients.

As per the study "Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis," published in November 2021, the number of adults globally with diabetic retinopathy was estimated to be 103.12 million in 2020, and by 2045, the numbers are projected to increase to 160.50 million. Thus, the growing burden of retinal diseases such as diabetic retinopathy may increase the demand for biologic treatment, which is expected to further drive the market growth.

Furthermore, in February 2022, Eyebiotech Limited secured USD 65 million in a series A financing round for developing a diverse pipeline of therapies for eye diseases such as wet age-related macular degeneration, diabetic retinopathy, etc. Therefore, rising investments may also boost innovation in the studied market, thereby driving the studied market growth.

However, the stringent regulatory process and initial high capital investment are the major restraining factors for the retinal biologics market.

Retinal Biologics Industry Segmentation

As per the report's scope, biologics are generally produced from living organisms such as microorganisms or animal or plant cells. Retinal biologics refer to bioengineered molecules implanted inside the eyes to heal chronic retinal diseases. The retinal biologics market is segmented by drug class (VEGF-A Antagonist, TNF-a Inhibitor), disease indication (macular degeneration, diabetic retinopathy, uveitis, others), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD million) for the above segments.

By Drug Class
VEGF-A Antagonist
TNF-a Inhibitor
By Disease Indication
Macular Degeneration
Diabetic Retinopathy
Other Disease Indications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Retinal Biologics Market Trends

This section covers the major market trends shaping the Retinal Biologics Market according to our research experts:

Diabetic Retinopathy Shows Lucrative Opportunity in the Global Retinal Biologics Market

Diabetic retinopathy (DR) is a microvascular complication caused by high blood sugar due to diabetes. Too much sugar in the blood over time damages the retina. Factors such as growing diabetes, increasing research and development, and the launch of the product are driving the market segment's growth over time. According to the article published by International Diabetes Federation in March 2020, the devastating consequences of diabetes mellitus are set to continue due to the predicted increase in prevalence from 463 million in 2019 to 700 million in 2045. Among this diabetic population, the global prevalence of diabetic retinopathy (DR) and diabetic macular edema (DME) for 2019 was 27.0%. The lowest prevalence was in Europe at 20.6% and South East Asia at 12.5%, and the highest in Africa at 33.8%, the Middle-East and North Africa at 33.8%, and the Western Pacific region at 36.2%.

The market segment growth is also contributed by the launch of products and approval from the global regulatory authorities. For Instance, in May 2019, Regeneron Pharmaceuticals, Inc. received United States Food and Drug Administration (FDA) approval for EYLEA (aflibercept) Injection to treat all stages of diabetic retinopathy. Such approvals are driving the growth of the market over the forecast period.

The most clinically important risk factors for progression to vision loss include the duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure are effective in preventing vision loss due to DR. Hence, the rising prevalence of DR and the growing awareness and concern over it are expected to drive the segment growth over the forecast period.

Retinal Biologics Market: Estimated number of People with Diabetes (in Millions), Global, 2021-2045

North America Dominates the Global Retinal Biologics Market

The primary driving factors for the growth of the North American retinal biologics market are the rising burden of retinal diseases, the growing burden of the diabetic population in the region, the rise in research and development activities, increasing product launches, and rising strategic initiatives by key market players.

The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, as per the article published by International Diabetes Federation, in December 2021, 51 million adults aged between 20-79 years were living with diabetes in the North America and Caribbean Region in 2021. This number is estimated to increase to 57 million by 2030 and 63 million by 2045.

According to the data published by the Centers for Disease Control and Prevention (CDC), in 2020, around 4.1 million Americans were affected with diabetic retinopathy, and nearly 900,000 Americans were threatened with vision-damaging retinopathy. Diabetic retinopathy is one of the leading disorders of posterior segment eye disorders. Increasing prevalence may increase the demand for treatment in a huge population which may boost the market growth in the country.

Moreover, strategic initiatives taken by the key market players, such as product launches, partnerships, initiation of new programs, and mergers and acquisitions, may drive market growth. For instance, in October 2021, Novartis received the United States Food and Drug Administration (FDA) for the company’s supplemental Biologics License Application (sBLA) for the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME). In July 2021, Genentech, a member of the Roche Group, announced that the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for faricimab for the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy.

Retinal Biologics Market- Growth Rate By Region

Retinal Biologics Industry Overview

The retinal biologics market is competitive and consists of a few major players. The strategies such as mergers and acquisitions adopted by the key market player may boost the market growth. Companies like F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, and Oxurion NV, among others, hold a substantial market share in the market.

Retinal Biologics Market Leaders

  1. F. Hoffmann-La Roche Ltd

  2. Regeneron Pharmaceuticals Inc.

  3. AbbVie Inc.

  4. MeiraGTx Limited

  5. Oxurion NV

*Disclaimer: Major Players sorted in no particular order

Retinal Biologics Market Concentration

Retinal Biologics Market News

  • In April 2022, Shilpa Biologicals (SBPL) received an NoC from RCGM, Dept of Biotechnology, to approach the Drugs Controller General of India (DCGI) to conduct clinical studies for its Biosimilar Aflibercept for the Wet Age-Related Macular Degeneration (wAMD), Diabetic Retinopathy, Diabetic Macular Edema (DME) and Macular Edema following Retinal Vein Occlusion markets in India and globally.
  • In January 2022, the Food and Drug Administration approved Roche for an eye disorder that could cause blindness in older people, called Vabysmo, for wet age-related macular degeneration.

Retinal Biologics Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Retinal Diseases and Increasing Diabetic Patient Population

      2. 4.2.2 Increasing R&D Activities and Growing Number of FDA Approvals

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Process and Initial High Capital Investment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - UDS Million)

    1. 5.1 By Drug Class

      1. 5.1.1 VEGF-A Antagonist

      2. 5.1.2 TNF-a Inhibitor

    2. 5.2 By Disease Indication

      1. 5.2.1 Macular Degeneration

      2. 5.2.2 Diabetic Retinopathy

      3. 5.2.3 Uveitis

      4. 5.2.4 Other Disease Indications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche Ltd

      2. 6.1.2 Regeneron Pharmaceuticals Inc.

      3. 6.1.3 AbbVie Inc.

      4. 6.1.4 MeiraGTx Limited

      5. 6.1.5 Oxurion NV

      6. 6.1.6 Novartis

      7. 6.1.7 GenSight Biologics

      8. 6.1.8 Adverum Biotechnologies

      9. 6.1.9 SemaThera Inc.

      10. 6.1.10 Amgen

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Retinal Biologics Market Research FAQs

The Global Retinal Biologics Market is studied from 2018 - 2028.

The Global Retinal Biologics Market is growing at a CAGR of 6.8% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2018 - 2028.

North America holds highest share in 2021.

F. Hoffmann-La Roche Ltd , Regeneron Pharmaceuticals Inc. , AbbVie Inc. , MeiraGTx Limited, Oxurion NV are the major companies operating in Global Retinal Biologics Market.

Global Retinal Biologics Industry Report

Statistics for the 2023 Global Retinal Biologics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Retinal Biologics analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!